Aurinia and Sun Pharmaceuticals settle patent challenge for LUPKYNIS®.

Aurinia Pharmaceuticals Stock

Aurinia (NASDAQ: AUPH) has announced that it has reached a settlement with Sun Pharmaceuticals in regards to a patent challenge for LUPKYNIS® (voclosporin). Due to this news, the share of Aurinia Pharmaceuticals has gained 38.66% today and Also the share of Aurinia Pharmaceuticals has reached from the closing price of USD 4.33 on January 2 to USD 5.64 on January 3.

Why Aurinia Pharmaceuticals Stock Soared 38%?

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) has announced that it has reached a settlement with Sun Pharmaceutical Industries, Sun Pharmaceuticals Industries, and Sun Pharma Global FZE (collectively known as Sun Pharmaceuticals). The settlement includes the filing of a joint motion to end the ongoing Inter Partes Review (IPR) concerning Aurinia’s US Patent No. 10,286,036 and the resolution of ongoing patent infringement litigation in the United States related to Sun’s CEQUA® product. In order for the settlement to be finalized, it must be approved by the US Patent Trial and Appeal Board. Under the terms of the agreement, both parties will dismiss their current claims and counterclaims against each other and will not take any further legal action against the other in the future.


LUPKYNIS is a drug that has been approved by the FDA for the treatment of lupus nephritis (LN). LN is a condition that can lead to permanent kidney damage and significantly increases the risk of kidney failure, heart problems, and death. It is a common and serious complication of the autoimmune disorder systemic lupus erythematosus (SLE). LUPKYNIS is available in both the United States and European Union.

Lupus Nephritis About:

Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE), a chronic and complex autoimmune disease that affects 200,000-300,000 people in the United States. It is estimated that one-third of people with SLE are diagnosed with LN at the time of their SLE diagnosis, and approximately 50% of all individuals with SLE may develop LN. If left untreated, LN can result in permanent and irreversible damage to the kidneys. Black and Asian people with SLE are four times more likely to develop LN and individuals of Hispanic heritage are about twice as likely to develop the disease compared to Caucasians. Black and Hispanic people with SLE also tend to develop LN earlier and have worse outcomes compared to Caucasians.

Aurinia Pharmaceuticals About:

Aurinia Pharmaceuticals is a biopharmaceutical company that is committed to providing therapies for patients suffering from serious diseases that have a high unmet medical need. In January 2021, the company launched LUPKYNIS® (voclosporin), the first FDA-approved oral treatment for adult patients with active lupus nephritis (LN). Aurinia has its headquarters in Victoria, British Columbia, its US commercial operations are based in Rockville, Maryland, and the company conducts its development efforts globally.

For Latest News Click Here

Leave a Reply

Your email address will not be published. Required fields are marked *